Most Read Articles
01 Oct 2013

Heart disease is still New Zealand’s biggest killer, with one Kiwi dying from coronary heart disease every 90 minutes. Pharmacy Today New Zealand looks at how pharmacists can help

Pearl Toh, 11 Oct 2017
Clinical practice is an art guided by good science, and clinical practice guideline (CPG) is meant to guide in integrating the art and science of clinical practice for the long-term benefits of patients, said Dr Abdul Rashid Abdul Rahman, a consultant cardiovascular physician at An-Nur Specialist Hospital in Bangi, Malaysia, during the 13th Asian-Pacific Congress of Hypertension (APCH) held in Singapore.
08 Oct 2017
Treatment with vismodegib does not appear to increase the risk of subsequent squamous cell carcinoma (SCC) in comparison with standard surgical treatment of basal cell carcinoma (BCC), a recent study suggests.
01 Sep 2017
Complementary medicines can play an important part in maintaining wellness, preventing deficiencies and optimizing health outcomes, says Dr Lesley Braun PhD, Director of the Blackmores Institute. 

Double dose of kisspeptin-54 improves oocyte yield in women at high risk of OHSS

Elaine Soliven
27 Sep 2017

A second dose of kisspeptin-54 improves oocyte yield in women at high risk of ovarian hyperstimulation syndrome (OHSS) during in vitro fertilization (IVF) treatment, according to a recent study.

“[A] second dose of kisspeptin-54 is a safe option in patients undergoing IVF treatment to further optimize oocyte maturation, even those at high risk of OHSS,” said the researchers. “Further studies are warranted to directly compare kisspeptin-54 to more established triggers of oocyte maturation.”

Sixty-two women with intact ovaries (aged 18–34 years, median body mass index 18–29 kg/m2) undergoing a single IVF cycle received kisspeptin-54 (9.6 nmol/kg) injected subcutaneously at 36 hours prior to oocyte retrieval. Patients were randomized in a 1:1 ratio to a single dose or double dose of kisspeptin-54, the latter administered 10 hours after the first dose to trigger oocyte maturation.

More women in the double-dose group achieved an oocyte yield of ≥60 percent than those in the single-dose group (71 percent [n=22] vs 45.2 percent [n=14]; difference, 25.8 percent, 95 percent confidence interval, 2.1–49.5 percent; p=0.042). [Hum Reprod 2017;32:1915-1924]

Implantation rates were significantly higher in women who received a double dose of kisspeptin-54 than a single dose (37 percent vs 23.3 percent). Live birth rates were also higher with double dose vs single dose of kisspeptin-54 (39 percent vs 19.4 percent).

The oocyte maturation rate was 82 percent for both treatment groups, where all patients in the double-dose group had at least one mature oocyte that was retrieved and fertilized to form an embryo for transfer.

One woman in the single-dose group had an unexplained miscarriage during the second trimester of pregnancy (19 weeks of gestation).

There was no difference in the incidence of OHSS between the two groups. One woman in the single-dose group was diagnosed with moderate, early OHSS, and one woman in the double-dose group had mild, late OHSS.

“Despite the study population being at high risk of developing OHSS, a second dose of kisspeptin-54 did not increase the occurrence of excessive ovarian response or OHSS,” noted the researchers.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 Oct 2013

Heart disease is still New Zealand’s biggest killer, with one Kiwi dying from coronary heart disease every 90 minutes. Pharmacy Today New Zealand looks at how pharmacists can help

Pearl Toh, 11 Oct 2017
Clinical practice is an art guided by good science, and clinical practice guideline (CPG) is meant to guide in integrating the art and science of clinical practice for the long-term benefits of patients, said Dr Abdul Rashid Abdul Rahman, a consultant cardiovascular physician at An-Nur Specialist Hospital in Bangi, Malaysia, during the 13th Asian-Pacific Congress of Hypertension (APCH) held in Singapore.
08 Oct 2017
Treatment with vismodegib does not appear to increase the risk of subsequent squamous cell carcinoma (SCC) in comparison with standard surgical treatment of basal cell carcinoma (BCC), a recent study suggests.
01 Sep 2017
Complementary medicines can play an important part in maintaining wellness, preventing deficiencies and optimizing health outcomes, says Dr Lesley Braun PhD, Director of the Blackmores Institute.